TheraRadar
Clinical-Stage Companies / Seikagaku Corporation

Seikagaku Corporation

Pre-Approval PRO BETA
⚫

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 7/28/2022

9
Total Trials
6
Phase 3
5
Phase 2
0
Recruiting
133
Score

Pipeline by Phase

Phase 3
6
Phase 2
5
Phase 1
1

Therapeutic Focus

Dry Eye Syndromes Intervertebral Disc Disease Lumbar Disc Disease Dry Eye Disease Lumbar Disc Herniation

Clinical Trials (9)

NCT05411367 Phase 3 COMPLETED

A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye

Started: 7/28/2022

NCT03607838 Phase 3 COMPLETED

SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

Started: 11/7/2018

NCT01941563 Phase 3 COMPLETED

A Study of SI-6603 in Patients With Lumbar Disc Herniation

Started: 9/1/2013

NCT02421601 Phase 3 COMPLETED

A Study of SI-6603 in Patients With Lumbar Disc Herniation

Started: 3/1/2015

NCT02205840 Phase 2 COMPLETED

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.

Started: 7/1/2014

NCT01558999 Phase 2 COMPLETED

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye

Started: 3/1/2012

NCT00634946 Phase 2 COMPLETED

SI-6603 Versus Placebo in Patients With Lumbar Disc Herniation

Started: 1/1/2008

NCT03209362 Phase 2 COMPLETED

SI-613 Study for Knee Osteoarthritis

Started: 10/19/2017

NCT04208087 Phase 1 COMPLETED

PK and Safety of SI-722 in IC/BPS

Started: 3/30/2020

Drug Candidates

SI-614 Placebo SI-6603 Sham injection SI-722 Vehicle High concentration SI-614 Low concentration SI-614 Condoliase placebo
Activity Status: Inactive
Last Trial Started: 7/28/2022
Last Trial Ended: 4/27/2023
Trials (12 months): 0
Completed Trials: 9
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.